lets start the week with something positive, page-29

I am hoping and praying for all sufferers of cancer and all PRR shareholders that the next few weeks/months bring some very positive announcements. You all deserve the success that "should" IMO, come your way this year!

Regarding using CVac on other Mucin 1 positive cancers, the below statement from our former illustrious leader MR is worth contemplating for PRR's potential future direction:

"One must balance the window of application for a label to running the clinical trial cost and time for the application with the US and EU. What is stock standard in the biotech industry is to apply for a label and then run clinical trials after marketing approval in US and EU for a “label expansion” this can be done on anecdotal evidence typically from oncologists using the product outside of label. In the US for instance it is ok for doctors to use a drug off-label and is very common, however, it is illegal in the US for a company to market a drug off-label. The remedy to increase the label is to run other studies."